On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) for treating atopic dermatitis (AD), the most common type of eczema affecting millions in the U.S. This once-daily, steroid-free cream could become a new standard of care for AD.
New AI tool can help select the most suitable treatment for cancer patients
A new artificial intelligence (AI) tool that can help to select the most suitable treatment for cancer patients has been developed by researchers at The
July 3, 2024